|
Physician Post-Marketing Survey on 500 Alpha-Stim Patients
|
Condition
|
N
|
Worse
|
No Change
|
Slight
<24%
|
Fair
25-49%
|
Moderate
50-74%
|
Marked
75-99%
|
Complete
100%
|
Significant
>25%
|
|
Pain
|
286
|
0.35%
|
1.75%
|
6.99%
|
16.78%
|
26.92%
|
37.76%
|
9.44%
|
90.91%
|
|
Anxiety
|
349
|
0.00%
|
2.29%
|
4.01%
|
11.17%
|
25.50%
|
51.86%
|
5.16%
|
93.70%
|
|
Depression
|
184
|
0.00%
|
4.35%
|
5.98%
|
16.85%
|
20.65%
|
44.57%
|
7.61%
|
89.67%
|
|
Stress
|
259
|
0.00%
|
2.32%
|
4.63%
|
14.29%
|
27.03%
|
47.88%
|
3.86%
|
93.05%
|
|
Insomnia
|
135
|
0.00%
|
11.85%
|
8.89%
|
12.59%
|
25.19%
|
33.33%
|
8.15%
|
79.26%
|
|
Headache
|
151
|
0.66%
|
5.30%
|
3.97%
|
16.56%
|
21.19%
|
41.72%
|
10.60%
|
90.07%
|
|
Muscle
Tension
|
259
|
0.77%
|
2.32%
|
2.32%
|
16.22%
|
29.34%
|
42.86%
|
6.18%
|
94.59%
|
|
Results of using Alpha-Stim technology as reported by healthcare practitioners. Total N = 500 patients with multiple symptoms. For additional information see the book: Kirsch, Daniel L. The Science Behind Cranial Electrotherapy Stimulation. Medical Scope Publishing Corporation, Edmonton, Alberta, Canada, 1999.
Peer-Reviewed Outcomes on 2,500 Alpha-Stim Patients Self-Reports
|
Condition
|
N
|
Slight
<24%
|
Fair
25-49%
|
Moderate
50-74%
|
Marked
75-100%
|
Significant
>25%
|
|
Pain (all cases)
|
1949
|
6.98%
|
31.97%
|
38.02%
|
23.04%
|
93.02%
|
|
Back Pain
|
403
|
4.96%
|
27.05%
|
38.96%
|
29.03%
|
95.04%
|
|
Cervical Pain
|
265
|
6.79%
|
26.04%
|
47.17%
|
20.00%
|
93.21%
|
|
Hip/Leg/Foot Pain
|
160
|
3.75%
|
26.88%
|
33.13%
|
36.25%
|
96.25%
|
|
Shoulder/Arm/Hand Pain
|
150
|
8.67%
|
27.33%
|
42.00%
|
22.00%
|
91.33%
|
|
Carpal Tunnel
|
25
|
0.00%
|
20.00%
|
68.00%
|
12.00%
|
100.00%
|
|
Arthritis Pain
|
188
|
5.85%
|
27.13%
|
46.81%
|
20.21%
|
94.15%
|
|
TMJ Pain
|
158
|
10.76%
|
37.97%
|
37.97%
|
13.29%
|
89.24%
|
|
Myofascial Pain
|
62
|
9.68%
|
29.03%
|
29.03%
|
32.26%
|
90.32%
|
|
RSD
|
55
|
18.18%
|
29.09%
|
34.55%
|
18.18%
|
81.82%
|
|
Fibromyalgia (alone)
|
142
|
9.15%
|
37.32%
|
36.62%
|
16.90%
|
90.85%
|
|
Fibromyalgia (with other)
|
363
|
9.09%
|
36.09%
|
41.87%
|
12.95%
|
90.91%
|
|
Migraine
|
118
|
1.69%
|
41.53%
|
25.42%
|
31.36%
|
98.31%
|
|
Headaches (all other)
|
112
|
17.86%
|
26.79%
|
21.43%
|
33.93%
|
82.14%
|
|
Psychological (all cases)
|
723
|
8.44%
|
24.20%
|
32.78%
|
34.58%
|
91.56%
|
|
Anxiety (alone)
|
128
|
10.16%
|
22.66%
|
32.81%
|
34.38%
|
89.84%
|
|
Anxiety (with other)
|
370
|
8.92%
|
22.97%
|
32.97%
|
35.14%
|
91.08%
|
|
Anxiety/Depression
|
58
|
5.17%
|
32.76%
|
32.76%
|
29.31%
|
94.83%
|
|
Depression (alone)
|
53
|
13.21%
|
20.75%
|
43.40%
|
22.64%
|
86.79%
|
|
Depression (with other)
|
265
|
10.94%
|
23.02%
|
35.09%
|
30.94%
|
89.06%
|
|
Stress
|
123
|
4.88%
|
24.39%
|
31.71%
|
39.02%
|
95.12%
|
|
Chronic Fatigue
|
50
|
6.00%
|
60.00%
|
20.00%
|
14.00%
|
94.00%
|
|
Insomnia
|
163
|
6.13%
|
28.83%
|
28.83%
|
36.20%
|
93.87%
|
|
Results of using Alpha-Stim technology at least 3 weeks from consecutive warranty cards. Total N = 2,500 patients with multiple symptoms. For additional information see: Smith, Ray B. Is microcurrent stimulation effective in pain management? An additional perspective. American Journal of Pain Management, 11(2):62-66, 2001.
See abstracts of additional Alpha-Stim research.
|
